How to Use Adjunctive CBT in Bipolar Disorder
How should clinicians use cognitive-behavioral therapy alongside medication for patients with bipolar disorder?
Patients with bipolar disorder often continue to have residual symptoms, adherence problems, and impaired functioning despite pharmacotherapy alone. This guide applies when a clinician is deciding whether to add cognitive-behavioral therapy to standard care and what treatment goals are realistically supported by the evidence.
-
Use CBT as an adjunct rather than a replacement
Add cognitive-behavioral therapy to standard care that already includes medication and clinical management. In the randomized trials summarized in this meta-analysis, CBT was always studied as adjunctive treatment rather than as a stand-alone intervention.
-
Target short-term symptom and adherence goals
Use adjunctive CBT when the clinical aim is to improve clinical symptoms, cognitive-behavioral mechanisms, treatment adherence, or quality of life in the short term. At posttreatment, CBT showed significant effects for clinical symptoms (d = -0.44), cognitive-behavioral etiopathogenetic mechanisms (d = -0.49), treatment adherence (d = -0.53), and quality of life and life or social adjustment (d = -0.36).
-
Do not rely on CBT to prevent relapse or recurrence
Do not present adjunctive CBT as a proven strategy for reducing relapse or recurrence in bipolar disorder based on this evidence set. The posttreatment effect on relapse and or recurrence was low and nonsignificant (d = -0.28), and relapse or recurrence remained nonsignificant across follow-up periods.
-
Set expectations that benefits are modest
Explain that the overall benefit of adjunctive CBT is significant but generally in the low to medium range rather than large. The pooled posttreatment effect size was d = -0.42, and after correcting for sample size it remained significant but smaller at D = -0.20.
-
Plan follow-up monitoring after therapy ends
Monitor patients after completion of CBT rather than assuming gains will persist unchanged. Benefits were more evident at posttreatment than during follow-up, with overall effects from posttreatment to 6 months at d = -0.27, from more than 6 to 12 months at d = -0.41, and beyond 12 months becoming nonsignificant after sample-size correction (D = -0.06).
-
Prioritize ongoing assessment of symptoms and adherence over functional recovery alone
During follow-up, pay particular attention to clinical symptoms and cognitive-behavioral mechanisms, because these were the most consistent domains showing continued benefit. Quality of life and life or social adjustment were significant at posttreatment but were not significantly improved during follow-up, and treatment adherence was not consistently significant across all later intervals.
-
Reassure patients that adding CBT does not appear to increase treatment costs
When discussing feasibility, note that this meta-analysis found no significant effect of CBT on treatment costs. The authors concluded that adding CBT to medication provided significant benefits without increasing overall treatment costs.
Clinical Considerations
- The evidence comes from 12 randomized clinical trials, but only 3 studies had more than 100 patients.
- Follow-up findings were unstable, and one large trial with nonsignificant outcomes substantially influenced the long-term results.
- The trials were heterogeneous in patient clinical status, outcome reporting, and follow-up intervals, which limits direct protocol standardization.
- The analysis could not rigorously separate CBT-specific effects from general psychotherapy factors because only 2 randomized trials compared CBT with other psychosocial interventions.
Bottom Line
Use cognitive-behavioral therapy as an adjunct to medication in bipolar disorder when the goal is short-term improvement in symptoms and adherence, but do not count on it alone to prevent relapse or maintain functional gains over time.
